The agent assembled a coherent overview of GSK's business, therapeutic focus, and market position by combining sparse site homepage content with web-search-sourced product details and competitor context. The site itself offers minimal product specificity and no pricing transparency, forcing reliance on external financial filings and research to answer core parts of the task.

• ›GSK's homepage provides strategic positioning (four therapeutic areas, 2.5B-person impact goal) but zero concrete product names, forcing the agent to fetch a /en-gb/products page that also withheld specific medications and instead directed users to an inaccessible Products A-Z section.
• ›No pricing information appears anywhere on the site; the agent correctly identified this as intentional (prices vary by region and market), but had to flag it as a notable omission rather than extract it from site content.
• ›The agent discovered specific product names (Dovato, Shingrix, Arexvy, Cabenuva) and Q1 2025 revenue figures entirely from SEC filings and external sources via web search, not from gsk.com itself—these facts are central to the answer but unavailable on the domain.
• ›GSK's website provides no explicit competitive comparisons; the agent's differentiation narrative (focused vs. broad portfolio, vaccine leadership, responsibility integration) came from homepage claims, but the competitor landscape (Pfizer, Merck, J&J, Roche, AstraZeneca) and relative strengths were sourced only from search results.
• ›The site's internal navigation failed at a critical juncture: the /en-gb/products page referenced a Products A-Z section and product area pages, but these were either unlinked, broken (404 on /en-gb/products/our-medicines), or inaccessible, leaving the agent unable to complete on-site discovery.